Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tas-115. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 20/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 18/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 1.00 |
| ▸ | KIT | P10721 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tas-115 SCHEMBL1132590 | 1.00 | MET (1.00) | METKDRPDGFRAPDGFRBAXL | |
| Tas-115 SCHEMBL16782348 | 0.97 | MET (0.94) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL23677959 | 0.93 | MET (0.87) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL1132734 | 0.93 | MET (0.88) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL1132173 | 0.93 | MET (0.86) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL20248763 | 0.92 | MET (0.86) | METKDRPDGFRAPDGFRBAXL | |
| Hydrochloric Acid SCHEMBL1132605 | 0.92 | MET (0.86) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL25129971 | 0.92 | MET (0.86) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL23761102 | 0.92 | MET (0.85) | METKDRPDGFRAPDGFRBAXL | |
| SCHEMBL1132166 | 0.92 | MET (0.85) | METKDRPDGFRAPDGFRBAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-06 | — | — | US | claimed |
| EP-3315131-B1 | THERAPEUTIC AGENT FOR FIBROSIS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2022-09-14 | — | — | EP | claimed |
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-06 | — | — | US | disclosed |
| EP-4105200-A1 | METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107889-A1 | PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND | AGPAT2, ACAT2, AADAC | MET 2207/4885KDR 4382/4885PDGFRA 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.